Monopar Therapeutics Inc. Increase (Decrease) in Other Current Assets
Monopar Therapeutics Inc. (MNPR) reported Increase (Decrease) in Other Current Assets of $400.86 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-08-12
- Monopar Therapeutics Inc. increase (decrease) in other current assets for the quarter ending 2026-06-30 was $213.82K.
- Monopar Therapeutics Inc. increase (decrease) in other current assets for the quarter ending 2026-03-31 was $187.04K, a 62.74% decline year-over-year.
- Monopar Therapeutics Inc. increase (decrease) in other current assets for the quarter ending 2025-12-31 was -$709.40K, a 2484.39% decline year-over-year.
- Monopar Therapeutics Inc. increase (decrease) in other current assets for the quarter ending 2025-09-30 was $321.27K.
- Monopar Therapeutics Inc. increase (decrease) in other current assets for fiscal 2025 was -$15.40K, a 220.57% decline from fiscal 2024.
- Monopar Therapeutics Inc. increase (decrease) in other current assets for fiscal 2024 was $12.78K, a 37.40% decline from fiscal 2023.
- Monopar Therapeutics Inc. increase (decrease) in other current assets for fiscal 2023 was $20.41K.
- Monopar Therapeutics Inc. increase (decrease) in other current assets for fiscal 2022 was -$171.75K.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 3 month as first filed | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 6 month as first filed | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 9 month as first filed | Increase (Decrease) in Other Current Assets 12 month | Increase (Decrease) in Other Current Assets 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $213.82K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $400.86K 10-Q · filed 2026-08-12 | -$308.54K derived: sum of 3 quarters · filed 2026-08-12 | $12.73K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2026-03-31 | $187.04K 10-Q · filed 2026-05-14 | -$522.36K derived: sum of 2 quarters · filed 2026-05-14 | -$201.10K derived: sum of 3 quarters · filed 2026-05-14 | -$330.40K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-12-31 | -$709.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$388.13K derived: sum of 2 quarters · filed 2026-03-27 | -$517.44K derived: sum of 3 quarters · filed 2026-08-12 | -$15.40K 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | $321.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $191.97K derived: sum of 2 quarters · filed 2026-08-12 | $694.00K 10-Q · filed 2025-11-13 | $723.75K derived: sum of 4 quarters · filed 2026-08-12 | ||||
| 2025-06-30 | -$129.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $372.73K 10-Q · filed 2026-08-12 | $586.76K 10-Q · filed 2025-08-12 | $402.48K derived: sum of 3 quarters · filed 2026-08-12 | $399.52K derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-03-31 | $502.03K 10-Q · filed 2026-05-14 | $621.54K 10-Q · filed 2025-05-13 | $531.79K derived: sum of 2 quarters · filed 2026-05-14 | $528.82K derived: sum of 3 quarters · filed 2026-05-14 | $478.95K derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $29.75K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $26.79K derived: sum of 2 quarters · filed 2026-03-27 | -$23.08K derived: sum of 3 quarters · filed 2026-03-27 | $12.78K 10-K · filed 2026-03-27 | $21.79K 10-K · filed 2025-03-31 | |||
| 2024-09-30 | -$2.96K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$52.83K derived: sum of 2 quarters · filed 2025-11-13 | -$16.98K 10-Q · filed 2025-11-13 | -$23.79K derived: sum of 4 quarters · filed 2025-11-13 | ||||
| 2024-06-30 | -$49.87K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$14.01K 10-Q · filed 2025-08-12 | -$20.82K derived: sum of 3 quarters · filed 2025-08-12 | -$57.49K derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $35.86K 10-Q · filed 2025-05-13 | $29.05K derived: sum of 2 quarters · filed 2025-05-13 | -$7.62K derived: sum of 3 quarters · filed 2025-05-13 | -$4.58K derived: sum of 4 quarters · filed 2025-05-13 | ||||
| 2023-12-31 | -$6.81K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$43.48K derived: sum of 2 quarters · filed 2025-03-31 | -$40.43K derived: sum of 3 quarters · filed 2025-03-31 | $20.41K 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | -$36.67K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | -$33.62K derived: sum of 2 quarters · filed 2024-11-08 | $27.22K 10-Q · filed 2024-11-08 | $17.48K derived: sum of 4 quarters · filed 2024-11-08 | ||||
| 2023-06-30 | $3.05K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $63.89K 10-Q · filed 2024-08-09 | $54.15K derived: sum of 3 quarters · filed 2024-08-09 | -$79.31K derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | $60.84K 10-Q · filed 2024-05-09 | -$60.84K 10-Q · filed 2023-05-11 | $51.10K derived: sum of 2 quarters · filed 2024-05-09 | -$82.36K derived: sum of 3 quarters · filed 2024-05-09 | -$135.02K derived: sum of 4 quarters · filed 2024-05-09 | |||
| 2022-12-31 | -$9.74K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$143.20K derived: sum of 2 quarters · filed 2024-03-28 | -$195.87K derived: sum of 3 quarters · filed 2024-03-28 | -$171.75K 10-K · filed 2024-03-28 | $171.75K 10-K · filed 2023-03-23 | |||
| 2022-09-30 | -$133.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$186.13K derived: sum of 2 quarters · filed 2023-11-09 | -$162.02K 10-Q · filed 2023-11-09 | $162.02K 10-Q · filed 2022-11-10 | -$204.10K derived: sum of 4 quarters · filed 2023-11-09 | |||
| 2022-06-30 | -$52.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$28.55K 10-Q · filed 2023-08-10 | -$70.64K derived: sum of 3 quarters · filed 2023-08-10 | -$147.63K derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $24.11K 10-Q · filed 2023-05-11 | -$24.11K 10-Q · filed 2022-05-12 | -$17.98K derived: sum of 2 quarters · filed 2023-05-11 | -$94.96K derived: sum of 3 quarters · filed 2023-05-11 | -$113.97K derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | -$42.09K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$119.07K derived: sum of 2 quarters · filed 2023-03-23 | -$138.08K derived: sum of 3 quarters · filed 2023-03-23 | -$86.20K 10-K · filed 2023-03-23 | ||||
| 2021-09-30 | -$76.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$95.99K derived: sum of 2 quarters · filed 2022-11-10 | -$44.11K 10-Q · filed 2022-11-10 | |||||
| 2021-06-30 | -$19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $32.88K 10-Q · filed 2022-08-11 | ||||||
| 2021-03-31 | $51.88K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |